These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12620642)

  • 1. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes.
    Avolio C; Ruggieri M; Giuliani F; Liuzzi GM; Leante R; Riccio P; Livrea P; Trojano M
    J Neuroimmunol; 2003 Mar; 136(1-2):46-53. PubMed ID: 12620642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
    Avolio C; Filippi M; Tortorella C; Rocca MA; Ruggieri M; Agosta F; Tomassini V; Pozzilli C; Stecchi S; Giaquinto P; Livrea P; Trojano M
    Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
    Waubant E; Goodkin D; Bostrom A; Bacchetti P; Hietpas J; Lindberg R; Leppert D
    Neurology; 2003 Jan; 60(1):52-7. PubMed ID: 12525717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.
    Waubant E; Goodkin DE; Gee L; Bacchetti P; Sloan R; Stewart T; Andersson PB; Stabler G; Miller K
    Neurology; 1999 Oct; 53(7):1397-401. PubMed ID: 10534241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
    Castellazzi M; Bellini T; Trentini A; Delbue S; Elia F; Gastaldi M; Franciotta D; Bergamaschi R; Manfrinato MC; Volta CA; Granieri E; Fainardi E
    Dis Markers; 2016; 2016():8434209. PubMed ID: 27340316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis.
    Liuzzi GM; Trojano M; Fanelli M; Avolio C; Fasano A; Livrea P; Riccio P
    Mult Scler; 2002 May; 8(3):222-8. PubMed ID: 12120694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
    Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
    Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
    Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
    Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis.
    Lichtinghagen R; Seifert T; Kracke A; Marckmann S; Wurster U; Heidenreich F
    J Neuroimmunol; 1999 Sep; 99(1):19-26. PubMed ID: 10496173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.